UBS has rated Novo Nordisk as a 'Buy', but the information provided is for informational purposes only and does not constitute a recommendation to buy or sell. Investing in securities carries risks, including the potential total loss of capital, and expert investment advice is recommended. No liability for the accuracy or completeness of the information is assumed, and the content is solely the responsibility of the authors, which may not reflect the views of wallstreetONLINE.